Stocks · News reference
Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pharmaceuticals. See what other analysts say.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
US equities mixed as tech stocks drag Nasdaq 100 lower, Trump escalates trade fight with Canada, and Fed Chair Warsh speaks at Jackson Hole.
Read original at benzingaRosenblatt analyst Scott Davis initiates coverage on Etsy (NYSE:ETSY) with a Buy rating and announces Price Target of $95.
Read original at benzingaWall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst ratings and price targets for these stocks.
Read original at benzingaB of A Securities analyst Curtis Nagle upgrades Etsy (NYSE:ETSY) from Neutral to Buy and raises the price target from $88 to $105.
Read original at benzingaThe multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.
Read original at globenewswire-incWall Street analysts changed outlook on top names. Check all rating changes, including upgrades/downgrades, on Benzinga analyst ratings page.
Read original at benzinga